Answers are grounded in this paper and cite their sources.
Analysis reveals gaps in adverse event reporting practices in drug-resistant tuberculosis facilities, indicating a need for improvement.
The reporting of adverse drug reactions associated with drug-resistant tuberculosis (DR-TB) medication is important for pharmacovigilance, especially in high burden countries such as South Africa. With DR-TB treatment being so dynamic, it is important to understand adverse event reporting practices at specialised facilities.
No takes yet. Share an insight, caveat, or question.
Human Sciences Research Council (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: